Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
COSCIENS Biopharma ( (TSE:CSCI) ) has shared an update.
On March 5, 2026, COSCIENS Biopharma announced it would cease funding its German subsidiaries Aeterna Zentaris GmbH and Zentaris IVF GmbH, which have historically housed its biopharmaceutical business centered on Macrilen, an FDA and EMA‑approved diagnostic test for adult growth hormone deficiency. The company expects these units to enter a structured insolvency process and to surrender rights to Macrilen, a move that follows disappointing Phase 3 trial results for a U.S. pediatric indication and unsuccessful efforts to find alternative expansion, sale, or licensing options.
Management said the decision, though difficult, is intended to significantly cut ongoing operating expenses and marks a key step toward profitability for the remaining business. COSCIENS plans to sharpen its focus on maximizing profitability in its active ingredients segment, suggesting a strategic pivot away from loss‑making biopharmaceutical operations toward its core plant‑based ingredient platform, with implications for shareholders, creditors of the German subsidiaries, and partners tied to Macrilen.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life sciences company focused on natural, plant‑based active ingredients for the skincare and nutraceutical markets. Leveraging proprietary manufacturing and extraction technologies, it develops avenanthramides and beta glucan ingredients that are already used in leading skincare brands worldwide, and has also pursued pharmaceutical assets through German subsidiaries.
Average Trading Volume: 2,303
Technical Sentiment Signal: Sell
Current Market Cap: C$7M
For a thorough assessment of CSCI stock, go to TipRanks’ Stock Analysis page.